Font size

We are always hopeful new drugs will be found that can take us closer to effective treatments and ultimately a cure.  IMP is incredibly disappointed to learn that Reneo Pharmaceuticals has terminated its Phase III Stride trial, which was seeking to examine the use of the drug mavodelpar in adult patients with primary mitochondrial myopathies.

To read more click here

© 2024 Int. Mito Patients